The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2020

Conditions
Gestational Diabetes Mellitus
Interventions
DRUG

Liraglutide

1.8 mg liraglutide

DRUG

Placebo

Liraglutide without the GLP-1 analogue

Trial Locations (1)

2900

Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, Hellerup

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

collaborator

Rigshospitalet, Denmark

OTHER

collaborator

Hvidovre University Hospital

OTHER

collaborator

Herlev Hospital

OTHER

collaborator

Hillerod Hospital, Denmark

OTHER

collaborator

University of Copenhagen

OTHER

collaborator

The Novo Nordisk Foundation Center for Basic Metabolic Research

OTHER

collaborator

Aarhus University Hospital

OTHER

lead

Tina Vilsboll

OTHER

NCT01795248 - The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes | Biotech Hunter | Biotech Hunter